NOT FOR DISTRIBUTION
Header cover image

Market Cap

€4.8b

Last Updated

2021/09/18 17:34 UTC

Data Sources

Company Financials +

Executive Summary

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential and pays a dividend.


Similar Companies

Share Price & News

How has Orion Oyj's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORNBV is less volatile than 75% of Finnish stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: ORNBV's weekly volatility (2%) has been stable over the past year.


Market Performance


7 Day Return

-0.3%

ORNBV

-0.6%

FI Pharmaceuticals

-4.2%

FI Market


1 Year Return

-14.0%

ORNBV

4.5%

FI Pharmaceuticals

19.8%

FI Market

Return vs Industry: ORNBV underperformed the Finnish Pharmaceuticals industry which returned 4.5% over the past year.

Return vs Market: ORNBV underperformed the Finnish Market which returned 19.8% over the past year.


Shareholder returns

ORNBVIndustryMarket
7 Day-0.3%-0.6%-4.2%
30 Day-0.5%-6.7%-2.9%
90 Day-7.8%1.6%2.0%
1 Year-10.1%-14.0%7.7%4.5%23.3%19.8%
3 Year21.5%7.8%42.8%27.2%39.8%18.8%
5 Year19.5%-2.6%54.0%27.9%75.8%41.1%

Long-Term Price Volatility Vs. Market

How volatile is Orion Oyj's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orion Oyj undervalued compared to its fair value and its price relative to the market?

24.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ORNBV (€34.32) is trading below our estimate of fair value (€45.67)

Significantly Below Fair Value: ORNBV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ORNBV is good value based on its PE Ratio (25.1x) compared to the European Pharmaceuticals industry average (27.2x).

PE vs Market: ORNBV is poor value based on its PE Ratio (25.1x) compared to the Finnish market (23.4x).


Price to Earnings Growth Ratio

PEG Ratio: ORNBV is poor value based on its PEG Ratio (3x)


Price to Book Ratio

PB vs Industry: ORNBV is overvalued based on its PB Ratio (6.9x) compared to the XE Pharmaceuticals industry average (3.5x).


Future Growth

How is Orion Oyj forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

8.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ORNBV's forecast earnings growth (8.3% per year) is above the savings rate (0.2%).

Earnings vs Market: ORNBV's earnings (8.3% per year) are forecast to grow faster than the Finnish market (7.4% per year).

High Growth Earnings: ORNBV's earnings are forecast to grow, but not significantly.

Revenue vs Market: ORNBV's revenue (4.2% per year) is forecast to grow faster than the Finnish market (3.7% per year).

High Growth Revenue: ORNBV's revenue (4.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ORNBV's Return on Equity is forecast to be high in 3 years time (30.9%)


Past Performance

How has Orion Oyj performed over the past 5 years?

-1.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORNBV has high quality earnings.

Growing Profit Margin: ORNBV's current net profit margins (18.7%) are lower than last year (23%).


Past Earnings Growth Analysis

Earnings Trend: ORNBV's earnings have declined by 1.8% per year over the past 5 years.

Accelerating Growth: ORNBV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ORNBV had negative earnings growth (-25.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.2%).


Return on Equity

High ROE: ORNBV's Return on Equity (27.5%) is considered high.


Financial Health

How is Orion Oyj's financial position?


Financial Position Analysis

Short Term Liabilities: ORNBV's short term assets (€616.0M) exceed its short term liabilities (€179.8M).

Long Term Liabilities: ORNBV's short term assets (€616.0M) exceed its long term liabilities (€163.1M).


Debt to Equity History and Analysis

Debt Level: ORNBV's debt to equity ratio (15%) is considered satisfactory.

Reducing Debt: ORNBV's debt to equity ratio has reduced from 35.3% to 15% over the past 5 years.

Debt Coverage: ORNBV's debt is well covered by operating cash flow (240.1%).

Interest Coverage: ORNBV's interest payments on its debt are well covered by EBIT (408.5x coverage).


Balance Sheet


Dividend

What is Orion Oyj current dividend yield, its reliability and sustainability?

4.37%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ORNBV's dividend (4.37%) is higher than the bottom 25% of dividend payers in the Finnish market (1.67%).

High Dividend: ORNBV's dividend (4.37%) is in the top 25% of dividend payers in the Finnish market (3.63%)


Stability and Growth of Payments

Stable Dividend: ORNBV's dividends per share have been stable in the past 10 years.

Growing Dividend: ORNBV's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (109.5%), ORNBV's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: ORNBV's dividends in 3 years are not forecast to be well covered by earnings (92.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.0yrs

Average management tenure


CEO

Timo Lappalainen (59 yo)

13.67yrs

Tenure

€2,363,226

Compensation

Mr. Timo Lappalainen, M.Sc. (Ind. Eng.), has been the Chief Executive Officer and President of Orion Oyj (Formerly, Orion Corporation) since January 2008. Mr. Lappalainen has been the Chairman of the Execu...


CEO Compensation Analysis

Compensation vs Market: Timo's total compensation ($USD2.77M) is about average for companies of similar size in the Finnish market ($USD2.40M).

Compensation vs Earnings: Timo's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: ORNBV's management team is seasoned and experienced (11 years average tenure).


Board Members

Experienced Board: ORNBV's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Orion Oyj's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orion Oyj
  • Ticker: ORNBV
  • Exchange: HLSE
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €4.829b
  • Shares outstanding: 140.56m
  • Website: https://www.orion.fi

Number of Employees


Location

  • Orion Oyj
  • Orionintie 1A
  • Espoo
  • Uusimaa
  • 2200
  • Finland

Listings


Biography

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and interna...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 17:34
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.